Covid-19 Vaccine Protection among Children and Adolescents in Qatar

The 10-μg dose of BNT162b2 led to modest, rapidly waning protection against Covid-19 in children 5 to 11 years old. The 30-μg dose in adolescents gave greater, more durable protection, more so in 12-to-14-year-olds than in 15-to-17-year-olds.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-11, Vol.387 (20), p.1865-1876
Hauptverfasser:	Chemaitelly, Hiam, AlMukdad, Sawsan, Ayoub, Houssein H., Altarawneh, Heba N., Coyle, Peter, Tang, Patrick, Yassine, Hadi M., Al-Khatib, Hebah A., Smatti, Maria K., Hasan, Mohammad R., Al-Kanaani, Zaina, Al-Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar H., Latif, Ali N., Shaik, Riyazuddin M., Abdul-Rahim, Hanan F., Nasrallah, Gheyath K., Al-Kuwari, Mohamed G., Al-Romaihi, Hamad E., Butt, Adeel A., Al-Thani, Mohamed H., Al-Khal, Abdullatif, Bertollini, Roberto, Abu-Raddad, Laith J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescents Age Antigens Children Children & youth Coronavirus Coronaviruses COVID-19 vaccines Hospitalization Immunization Infections Infectious Disease Laboratories Pediatrics Regression analysis Severe acute respiratory syndrome coronavirus 2 Teenagers Vaccination Vaccines Viral Infections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The 10-μg dose of BNT162b2 led to modest, rapidly waning protection against Covid-19 in children 5 to 11 years old. The 30-μg dose in adolescents gave greater, more durable protection, more so in 12-to-14-year-olds than in 15-to-17-year-olds.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2210058